# Tenax Therapeutics, Inc.: financial statements, quarterly

TENX · Nasdaq · CIK 34956 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tenx.md) · [Financials](/companies/tenx/financials.md) · [Filings](/companies/tenx/filings.md) · [Insiders](/companies/tenx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tenx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0000950170-25-071395.md) | [0.0 d](/filings/0000950170-25-108063.md) | [0.0 d](/filings/0001193125-25-277793.md) | [0.0 d](/filings/0001193125-26-099393.md) | [0.0](/filings/0001193125-26-219383.md) | [0.0 d](/filings/0001193125-26-327455.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [1.1](/filings/0001654954-24-014262.md) | [1.7 d](/filings/0000950170-25-044398.md) | [2.7](/filings/0000950170-25-071395.md) | [2.3](/filings/0000950170-25-108063.md) | [3.1](/filings/0001193125-25-277793.md) | [4.6 d](/filings/0001193125-26-099393.md) | [5.7](/filings/0001193125-26-219383.md) | [6.1](/filings/0001193125-26-327455.md) | [10.3](/filings/0001193125-25-277793.md) | [10.5 d](/filings/0001193125-26-099393.md) | [11.5](/filings/0001193125-26-219383.md) | [12.9](/filings/0001193125-26-327455.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [5.7](/filings/0001193125-26-327455.md) | not reported | not reported | not reported | [5.9](/filings/0001193125-26-327455.md) |
| Operating income | $m | [2.1](/filings/0001654954-24-014262.md) | [(13.1) d](/filings/0000950170-25-044398.md) | [(3.9)](/filings/0000950170-25-071395.md) | [(3.7)](/filings/0000950170-25-108063.md) | [(4.6)](/filings/0001193125-25-277793.md) | [(7.3) d](/filings/0001193125-26-099393.md) | [(11.3)](/filings/0001193125-26-219383.md) | [(11.8)](/filings/0001193125-26-327455.md) | [(16.8)](/filings/0001193125-25-277793.md) | [(16.4) d](/filings/0001193125-26-099393.md) | [(16.6)](/filings/0001193125-26-219383.md) | [(18.8)](/filings/0001193125-26-327455.md) |
| Interest expense | $m | [0.0](/filings/0001654954-24-014262.md) | [0.0 d](/filings/0000950170-25-044398.md) | [0.0](/filings/0000950170-25-071395.md) | [0.0](/filings/0000950170-25-108063.md) | [0.0](/filings/0001193125-25-277793.md) | [(0.0) d](/filings/0001193125-26-099393.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [2.0](/filings/0001654954-24-014262.md) | [(12.2) d](/filings/0000950170-25-044398.md) | [(3.8)](/filings/0001193125-25-277793.md) | [(3.6)](/filings/0001193125-25-277793.md) | [(4.0)](/filings/0001193125-25-277793.md) | [(6.3) d](/filings/0001193125-26-099393.md) | [(10.4)](/filings/0001193125-26-327455.md) | [(10.8)](/filings/0001193125-26-327455.md) | [(15.8)](/filings/0001193125-25-277793.md) | [(15.5) d](/filings/0001193125-26-099393.md) | [(15.7)](/filings/0001193125-26-327455.md) | [(17.8)](/filings/0001193125-26-327455.md) |
| Diluted EPS | $ per share | not reported | not reported | [(3.12)](/filings/0000950170-25-071395.md) | [(1.83)](/filings/0000950170-25-108063.md) | [(0.19)](/filings/0001193125-25-277793.md) | not reported | [(0.28)](/filings/0001193125-26-219383.md) | [(0.27)](/filings/0001193125-26-327455.md) | [(0.40)](/filings/0001193125-25-277793.md) | not reported | [(0.35)](/filings/0001193125-26-219383.md) | [(0.35)](/filings/0001193125-26-327455.md) |
| Basic EPS | $ per share | not reported | not reported | [(3.12)](/filings/0000950170-25-071395.md) | [(1.83)](/filings/0000950170-25-108063.md) | [(0.19)](/filings/0001193125-25-277793.md) | not reported | [(0.28)](/filings/0001193125-26-219383.md) | [(0.27)](/filings/0001193125-26-327455.md) | [(0.40)](/filings/0001193125-25-277793.md) | not reported | [(0.35)](/filings/0001193125-26-219383.md) | [(0.35)](/filings/0001193125-26-327455.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.3](/filings/0001654954-23-014168.md) | [9.8](/filings/0000950170-25-044398.md) | not reported | not reported | not reported | [94.9](/filings/0001193125-26-099393.md) | [111](/filings/0000950170-25-071395.md) | [106](/filings/0000950170-25-108063.md) | [99.4](/filings/0001193125-25-277793.md) | [97.6](/filings/0001193125-26-099393.md) | [119](/filings/0001193125-26-219383.md) | [118](/filings/0001193125-26-327455.md) |
| Current assets | $m | [11.9](/filings/0001654954-23-014168.md) | [11.7](/filings/0000950170-25-044398.md) | [14.5](/filings/0001654954-24-006228.md) | [10.6](/filings/0001654954-24-010456.md) | [99.8](/filings/0001654954-24-014262.md) | [96.7](/filings/0001193125-26-099393.md) | [112](/filings/0000950170-25-071395.md) | [106](/filings/0000950170-25-108063.md) | [103](/filings/0001193125-25-277793.md) | [104](/filings/0001193125-26-327455.md) | [123](/filings/0001193125-26-219383.md) | [122](/filings/0001193125-26-327455.md) |
| Total assets | $m | [11.9](/filings/0001654954-23-014168.md) | [11.7](/filings/0000950170-25-044398.md) | [14.5](/filings/0001654954-24-006228.md) | [10.6](/filings/0001654954-24-010456.md) | [99.8](/filings/0001654954-24-014262.md) | [96.7](/filings/0001193125-26-099393.md) | [112](/filings/0000950170-25-071395.md) | [106](/filings/0000950170-25-108063.md) | [103](/filings/0001193125-25-277793.md) | [104](/filings/0001193125-26-327455.md) | [123](/filings/0001193125-26-219383.md) | [122](/filings/0001193125-26-327455.md) |
| Current liabilities | $m | [0.6](/filings/0001654954-23-014168.md) | [3.6](/filings/0000950170-25-044398.md) | [2.0](/filings/0001654954-24-006228.md) | [1.7](/filings/0001654954-24-010456.md) | [2.6](/filings/0001654954-24-014262.md) | [4.7](/filings/0001193125-26-099393.md) | [2.8](/filings/0000950170-25-071395.md) | [2.5](/filings/0000950170-25-108063.md) | [6.6](/filings/0001193125-25-277793.md) | [7.2](/filings/0001193125-26-327455.md) | [8.5](/filings/0001193125-26-219383.md) | [8.1](/filings/0001193125-26-327455.md) |
| Total liabilities | $m | [0.6](/filings/0001654954-23-014168.md) | [3.6](/filings/0000950170-25-044398.md) | [2.0](/filings/0001654954-24-006228.md) | [1.7](/filings/0001654954-24-010456.md) | [2.6](/filings/0001654954-24-014262.md) | [4.7](/filings/0001193125-26-099393.md) | [2.8](/filings/0000950170-25-071395.md) | [2.5](/filings/0000950170-25-108063.md) | [6.6](/filings/0001193125-25-277793.md) | [7.2](/filings/0001193125-26-327455.md) | [8.5](/filings/0001193125-26-219383.md) | [8.1](/filings/0001193125-26-327455.md) |
| Shareholders' equity | $m | [11.3](/filings/0001654954-24-014262.md) | [8.1](/filings/0001193125-26-099393.md) | [12.4](/filings/0001193125-25-277793.md) | [8.9](/filings/0001193125-25-277793.md) | [97.2](/filings/0001193125-25-277793.md) | [92.0](/filings/0001193125-26-327455.md) | [109](/filings/0001193125-26-327455.md) | [103](/filings/0001193125-26-327455.md) | [96.2](/filings/0001193125-25-277793.md) | [97.1](/filings/0001193125-26-327455.md) | [115](/filings/0001193125-26-327455.md) | [114](/filings/0001193125-26-327455.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(2.1) d](/filings/0001654954-24-014262.md) | [(1.2) d](/filings/0000950170-25-044398.md) | [(5.2)](/filings/0000950170-25-071395.md) | [(3.0) d](/filings/0000950170-25-108063.md) | [(3.1) d](/filings/0001193125-25-277793.md) | [(3.5) d](/filings/0001193125-26-099393.md) | [(7.0)](/filings/0001193125-26-219383.md) | [(6.3) d](/filings/0001193125-26-327455.md) | [(9.2) d](/filings/0001193125-25-277793.md) | [(13.4) d](/filings/0001193125-26-099393.md) | [(9.3)](/filings/0001193125-26-219383.md) | [(14.2) d](/filings/0001193125-26-327455.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2014 (2014-01-31) | Q1 FY2015 (2014-07-31) | Q2 FY2015 (2014-10-31) | Q3 FY2015 (2015-01-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [10.3](/filings/0001354488-15-001191.md) | [27.7](/filings/0001354488-14-004652.md) | [28.1](/filings/0001354488-14-006182.md) | [28.1](/filings/0001354488-15-001191.md) | [1.2](/filings/0000950170-25-071395.md) | [2.0](/filings/0000950170-25-108063.md) | [21.2](/filings/0001193125-25-277793.md) | [36.6](/filings/0001193125-26-219383.md) | [39.6](/filings/0001193125-26-327455.md) | [39.7](/filings/0001193125-25-277793.md) | [45.2](/filings/0001193125-26-219383.md) | [50.9](/filings/0001193125-26-327455.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 37,423,917 at 2026-07-28, from the cover of the [10-Q filed 2026-07-31](/filings/0001193125-26-327455.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:18 ET. No prices; not investment advice.